@article{8e840b595f714bb395d2022a711956d3,
title = "The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper",
abstract = "The British Society for Haematology (BSH) produces Good Practice Papers to recommend good practice in areas where there is a limited evidence base but for which a degree of consensus or uniformity is likely to be beneficial to patient care. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. This Good Practice Paper was produced as a collaboration with the European Hematology Association (EHA) compiled according to the BSH process at http://scanmail.trustwave. com/?c=8248&d=68DV3b1jbPPsVn. This guideline group included UK-based medical experts representing the BSH and members of the EHA Red Cell and Iron Scientific Working Group (SWG).",
author = "Roy, {No{\'e}mi B.A.} and {Da Costa}, Lydie and Roberta Russo and Paola Bianchi and {Del Mar Ma{\~n}{\'u}-Pereira}, Maria and Elisa Fermo and Immacolata Andolfo and Barnaby Clark and Melanie Proven and Mayka Sanchez and {Van Wijk}, Richard and {Van Der Zwaag}, Bert and Mark Layton and David Rees and Achille Iolascon",
note = "Funding Information: The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH/EHA and Task Force Chairs. LDC received funding for an educational session at ASH. PB funding from the Ministry of Health. MdMMP received research grant and advisory board funding from Agios Pharmaceuticals and Novartis Pharmaceuticals. BC received research funding from Agios Pharmaceuticals. MS reports no relevant funding sources related to this manuscript; is co-founder of BloodGenetics (receives no financial support). RVW received research and staff funding from Agios Pharmaceuticals. ML received funding from Agios Pharmacueticals and Novartis. DR received grant funding unrelated to this manuscript from Agios. All remaining authors report no relevant financial disclosures. Publisher Copyright: {\textcopyright} 2022 Wolters Kluwer Health. All rights reserved.",
year = "2022",
month = jun,
day = "6",
doi = "10.1097/HS9.0000000000000739",
language = "English",
volume = "6",
journal = "HemaSphere",
issn = "2572-9241",
publisher = "Wolters Kluwer Health",
number = "6",
}